Devyser announced the launch of next generation chimerism analysis solution, strengthening its offering in post-transplant monitoring
One Lambda™ Devyser Chimerism Plus is a next generation solution for chimerism analysis following...
News | November 18, 2020
We’re happy to announce that we’ve received certification for the successful completion of a Quality Management System audit under the Medical Device Single Audit Program (MDSAP)!
The MDSAP is a stringent audit process that allows for a recognized auditing organization to conduct a single regulatory audit of a medical device manufacturer that, in addition to ISO13485:2016, satisfies the relevant requirements of the regulatory authorities participating in the program, including those in Canada, the United States, Brazil, Australia and Japan. Read more in today’s press release:
Stockholm, November 18, 2020 – Devyser, Swedish molecular diagnostics company, is pleased to announce that it has received certification for the successful completion of a Quality Management System audit under the Medical Device Single Audit Program (MDSAP).
The MDSAP is a stringent audit process that allows for a recognized auditing organization to conduct a single regulatory audit of a medical device manufacturer that, in addition to ISO13485:2016, satisfies the relevant requirements of the regulatory authorities participating in the program, including those in Canada, the United States, Brazil, Australia and Japan.
"Achieving the MDSAP certification confirms our ongoing commitment to maintaining the highest quality assurance standards within the In Vitro Diagnostic Medical Devices (IVD). The certification provides compliance in new jurisdictions enabling great potential for future market expansion and growth"
Says Fredrik Alpsten, CEO at Devyser Diagnostics AB.
"Delivering products that meet our customers’ high expectations is at the core of our business. The MDSAP certification is yet another token of this commitment, an achievement made possible by the entire Devyser staff and their unwavering focus on quality"
Says Olle Myrberg, Head of Quality Assurance at Devyser.
One Lambda™ Devyser Chimerism Plus is a next generation solution for chimerism analysis following...
Read More
Devyser, a leading provider of advanced genetic testing solutions, has been awarded a tender in...
Read More
Devyser, today announced the launch of Devyser Thalassemia v2, the first Next-Generation Sequencing...
Read More
Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announces that it has...
Read More